Adlai Nortye Ltd
NASDAQ:ANL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adlai Nortye Ltd
Cash Equivalents
Adlai Nortye Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Adlai Nortye Ltd
NASDAQ:ANL
|
Cash Equivalents
$8.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
B
|
Better Home & Finance Holding Co
NASDAQ:BETR
|
Cash Equivalents
$99.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
L
|
LAI YIH Footware Co Ltd
TWSE:6890
|
Cash Equivalents
NT$494.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
ITH Corp
TWSE:6962
|
Cash Equivalents
NT$917m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Chung Jye Investment Holding Co Ltd
TWSE:6965
|
Cash Equivalents
NT$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Armada Acquisition Corp II
NASDAQ:XRPN
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Adlai Nortye Ltd
Glance View
Adlai Nortye Ltd is a KY-based company operating in industry. Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
See Also
What is Adlai Nortye Ltd's Cash Equivalents?
Cash Equivalents
8.1m
USD
Based on the financial report for Dec 31, 2025, Adlai Nortye Ltd's Cash Equivalents amounts to 8.1m USD.
What is Adlai Nortye Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-20%
Over the last year, the Cash Equivalents growth was -87%. The average annual Cash Equivalents growth rates for Adlai Nortye Ltd have been -43% over the past three years , -20% over the past five years .
